Jennifer Fisher, MMSc, PA-C

Abrocitinib’s targeted inhibition of JAK1 offers effective control of AD, but may, in rare instances, lead to a shift in immune expression resulting in paradoxical psoriasis.

Explore the potential of GLP-1 receptor agonists in psoriasis management, highlighting their immunomodulatory effects and metabolic benefits for patients.

CD19 CAR T-cell therapy may modulate immune dysregulation in underlying diseases such as psoriasis.